What to do: Do not consume, use, sell, serve, or distribute the recalled product
Audience: General public; Hotels, restaurants and institutions
Hazard classification: Class 3
Affected products
Brand
Product
Size
UPC
Codes
Intercity Packers Ltd.
Oyster N/Shell Royal Miyagi Ow
Variable
None
Harvest Date: 03/29/22 Process Date: 03/30/22 Harvest Location: BC Area 15-4 LF#: 0195337
Harvest Date: 04/04/22 Process Date: 04/06/22 Harvest Location: BC Area 15-4 LF#: 0195337
Issue
Intercity Packers Ltd. is recalling Intercity Packers Ltd. brand Oyster N/Shell Royal Miyagi Ow from the marketplace due to possible norovirus contamination.
The recalled product has been sold in British Columbia and Ontario and may have been distributed in other provinces and territories.
What you should do
If you think you became sick from consuming a recalled product, call your doctor
Check to see if you have the recalled product in your home or establishment
Do not consume the recalled product
Do not serve, use, sell, or distribute the recalled product
Recalled products should be thrown out or returned to the location where they were purchased
Consumers who are unsure if they have purchased the affected product are advised to contact their retailer
People with norovirus illness usually develop symptoms of gastroenteritis within 24 to 48 hours, but symptoms can start as early as 12 hours after exposure. The illness often begins suddenly. Even after having the illness, you can still become re-infected by norovirus. The main symptoms of norovirus illness are diarrhea, vomiting (children usually experience more vomiting than adults), nausea and stomach cramps. Other symptoms may include low-grade fever, headache, chills, muscle aches and fatigue (a general sense of tiredness). Most people feel better within one or two days, with symptoms resolving on their own, and experience no long-term health effects. As with any illness causing diarrhea or vomiting, people who are ill should drink plenty of liquids to replace lost body fluids and prevent dehydration. In severe cases, patients may need to be hospitalized and given fluids intravenously.
This recall was triggered by findings by the Canadian Food Inspection Agency during its investigation into a foodborne illness outbreak.
The Public Health Agency of Canada is investigating an outbreak of human illness. Please refer to the Public Health Notice for further details on this active outbreak investigation.
What is being done
The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated food recall warnings.
The CFIA is verifying that industry is removing the recalled product from the marketplace.
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...